TILs Immunophenotype in Breast Cancer Predicts Local Failure and Overall Survival: Analysis in a Large Radiotherapy Trial with Long-Term Follow-Up.
breast cancer
immunophenotype
prognosis
tumour infiltrating lymphocytes (TILs)
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
21 Aug 2020
21 Aug 2020
Historique:
received:
13
07
2020
revised:
05
08
2020
accepted:
19
08
2020
entrez:
23
8
2020
pubmed:
23
8
2020
medline:
23
8
2020
Statut:
epublish
Résumé
To determine the prognostic significance of the immunophenotype of tumour-infiltrating lymphocytes (TILs) within a cohort of breast cancer patients with long-term follow-up. Multiplexed immunofluorescence and automated image analysis were used to assess the expression of CD3, CD8, CD20, CD68, Fox P3, PD-1 and PD-L1 in a clinical trial of local excision and radiotherapy randomised to a cavity boost or not ( LR was predicted by low CD8 in MVA in the whole cohort (HR 2.34, CI 1.4-4.02, Immunophenotype adds further prognostic data to help further stratify risk of LR and OS even in TILs low-luminal tumours.
Identifiants
pubmed: 32825588
pii: cancers12092365
doi: 10.3390/cancers12092365
pmc: PMC7563743
pii:
doi:
Types de publication
Journal Article
Langues
eng
Références
Front Immunol. 2018 Mar 08;9:470
pubmed: 29568299
Br J Cancer. 2011 Jul 12;105(2):272-80
pubmed: 21712826
J Natl Cancer Inst. 2009 May 20;101(10):736-50
pubmed: 19436038
Clin Cancer Res. 2009 Feb 1;15(3):1046-51
pubmed: 19188178
Breast Cancer Res Treat. 2012 Apr;132(2):545-53
pubmed: 21671016
Pathology. 2018 Apr;50(3):333-341
pubmed: 29429740
Breast Cancer Res. 2019 Aug 7;21(1):90
pubmed: 31391067
Oncologist. 2015 May;20(5):474-82
pubmed: 25908555
Breast Cancer Res. 2019 Dec 26;21(1):151
pubmed: 31878981
Ann Oncol. 2019 Dec 1;30(12):1941-1949
pubmed: 31566659
Trends Immunol. 2018 Aug;39(8):644-655
pubmed: 30001871
Ann Oncol. 2015 Feb;26(2):259-71
pubmed: 25214542
Cell Mol Immunol. 2008 Dec;5(6):401-6
pubmed: 19118505
J Natl Cancer Inst. 2020 Jul 1;112(7):737-746
pubmed: 31665365
Breast Cancer Res Treat. 2017 Nov;166(2):613-622
pubmed: 28791482
Clin Cancer Res. 2018 Dec 15;24(24):6125-6135
pubmed: 30049748
Breast Cancer Res. 2016 Jul 29;18(1):78
pubmed: 27473061
J Clin Oncol. 2009 Oct 1;27(28):4701-8
pubmed: 19720911
Breast Cancer Res Treat. 2020 Apr;180(2):369-377
pubmed: 32034580
J Immunother Cancer. 2019 Feb 6;7(1):34
pubmed: 30728081
J Clin Oncol. 2006 Dec 1;24(34):5373-80
pubmed: 17135638
Lancet. 2000 May 20;355(9217):1757-70
pubmed: 10832826
JAMA Oncol. 2016 Oct 1;2(10):1354-1360
pubmed: 27355489
Nature. 2020 Jan;577(7791):549-555
pubmed: 31942075
Histopathology. 2020 Feb 13;:
pubmed: 32056259
Ann Oncol. 2013 Sep;24(9):2206-23
pubmed: 23917950
Cancers (Basel). 2020 Apr 29;12(5):
pubmed: 32365629
Breast. 2018 Apr;38:66-74
pubmed: 29253718
Methods. 2014 Nov;70(1):46-58
pubmed: 25242720
J Immunother Cancer. 2016 Oct 18;4:59
pubmed: 27777769
J Clin Oncol. 2005 Dec 20;23(36):9067-72
pubmed: 16172462
Ann Oncol. 2014 Aug;25(8):1536-43
pubmed: 24915873
Adv Anat Pathol. 2017 Sep;24(5):235-251
pubmed: 28777142
J Natl Cancer Inst. 2018 Feb 1;110(2):
pubmed: 28859291
Sci Rep. 2016 Nov 04;6:36231
pubmed: 27812028
Clin Cancer Res. 2014 Dec 1;20(23):5995-6005
pubmed: 25255793
JAMA Oncol. 2019 Jul 18;:
pubmed: 31318407
Immunotherapy. 2019 Jun;11(8):691-704
pubmed: 30966845
J Clin Oncol. 2019 Mar 1;37(7):559-569
pubmed: 30650045
J Immunol. 2010 Nov 1;185(9):4977-82
pubmed: 20962266
Histopathology. 2020 Jul;77(1):79-91
pubmed: 32281132
Clin Cancer Res. 2013 May 15;19(10):2775-86
pubmed: 23493347
Lancet Oncol. 2018 Jan;19(1):40-50
pubmed: 29233559
Histopathology. 1991 Nov;19(5):403-10
pubmed: 1757079
Breast Cancer Res Treat. 2018 Sep;171(2):273-282
pubmed: 29858752